Stay updated on LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial
Sign up to get notified when there's something new on the LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial page.

Latest updates to the LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page displays the study record for the Phase I LMB-100 pleural cancer trial, including its withdrawn status with no participants enrolled, eligibility criteria, treatment plan, and outcome measures.SummaryDifference58%

- Check18 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH website updates and says the agency is using “Super Intelligence” in place of “Artificial Intelligence.” It appears above the page’s 403 error message.SummaryDifference1%

- Check32 days agoChange DetectedThe site's displayed revision advances from v3.7.1 to v3.7.2; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1, while the study record page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now renders a 403 Forbidden error page, including a DOCTYPE, a 403 title, and a Home link. This replaces the previous study details with a simple error layout.SummaryDifference20%

Stay in the know with updates to LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LMB-100 Immunotoxin in Pleural Mesotheliomas Clinical Trial page.